AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17060297 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15262457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg
Number of subjects: 50
Study 15262457 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine 20 mg
Number of subjects: 50
Study 15262457 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate 40 mg
Number of subjects: 50
Study 11200658 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl starch (ACS)
Number of subjects: 17
Study 11200658 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 17
Study 9257073 — intervention group
Group type: EXPERIMENTAL
Intervention: New antithrombotic drug
Number of subjects: 0
Study 9257073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8483109 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 200 mg orally every 4 hours (1,200 mg daily)
Number of subjects: 70
Study 8483109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2450237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol (nonselective beta‐adrenoceptor blocker)
Number of subjects: 8
Study 2450237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2450237 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 8
Study 28153503 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein mixture with added tryptophan (TRP)
Number of subjects: 32
Study 28153503 — intervention group
Group type: COMPARATOR
Intervention: Whey protein only (control)
Number of subjects: 32
Study 27518195 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg intravenous omeprazole (OME) bolus injection every 12 hours
Number of subjects: 41
Study 27518195 — intervention group
Group type: COMPARATOR
Intervention: 8-mg/h continuous intravenous infusion of omeprazole (OME) for 72 hours after an 80-mg i.v. OME bolus administration
Number of subjects: 41
Study 27518195 — intervention group
Group type: COMPARATOR
Intervention: 8-mg/h continuous intravenous infusion of omeprazole (OME) for 72 hours
Number of subjects: 41
Study 24548278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher™ stent
Number of subjects: 2098
Study 24548278 — intervention group
Group type: COMPARATOR
Intervention: Taxus™ stent
Number of subjects: 2098
Study 23406757 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 84
Study 23406757 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg daily)
Number of subjects: 84
Study 23406757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 20042452 — intervention group
Group type: EXPERIMENTAL
Intervention: Seawater gel nasal spray for 10 days
Number of subjects: 100
Study 20042452 — intervention group
Group type: EXPERIMENTAL
Intervention: Seawater gel
Number of subjects: 100
Study 20042452 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 18981767 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered interruption of NNRTI
Number of subjects: 688
Study 18981767 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched interruption of NNRTI
Number of subjects: 688
Study 18981767 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous interruption of NNRTI
Number of subjects: 688
Study 18981767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with detectable mutations
Number of subjects: 688
Study 18981767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without detectable mutations
Number of subjects: 688
Study 15755765 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin per day
Number of subjects: 10001
Study 15755765 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin per day
Number of subjects: 10001
Study 12868251 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exposure to a small, portable pulsing electromagnetic field generator
Number of subjects: 117
Study 12868251 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 117
Study 11825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidant therapy (specifics not provided)
Number of subjects: 0
Study 11825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (specifics not provided)
Number of subjects: 0
Study 11825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and synthetic anti-oxidants (specifics not provided)
Number of subjects: 0
Study 11825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of natural anti-oxidant vitamins (specifics not provided)
Number of subjects: 0
Study 11825313 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate markers of CVD (specifics not provided)
Number of subjects: 0
Study 9148349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg intravenous)
Number of subjects: 40
Study 9148349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7936855 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone for 5.36 ± 2.18 years
Number of subjects: 36
Study 7936855 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and phosphate therapy for 4.33 ± 2.19 years
Number of subjects: 36
Study 7936855 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone vs Vitamin D and phosphate therapy
Number of subjects: 36
Study 7936855 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and phosphate therapy added to Vitamin D alone
Number of subjects: 36
Study 3361212 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive bandage
Number of subjects: 108
Study 3361212 — intervention group
Group type: COMPARATOR
Intervention: Dorsal plaster cast
Number of subjects: 108
Study 31021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-puncture arthrocentesis
Number of subjects: 32
Study 31021311 — intervention group
Group type: COMPARATOR
Intervention: Double-puncture arthrocentesis
Number of subjects: 32
Study 31957726 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program on primary eye care (PEC) for ASHAs, one day training duration.
Number of subjects: 0
Study 28899995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile van testing for HIV
Number of subjects: 8756
Study 26908741 — intervention group
Group type: EXPERIMENTAL
Intervention: ogp160 MN/LAI-2 with polyphosphazene (pP)
Number of subjects: 91
Study 26908741 — intervention group
Group type: EXPERIMENTAL
Intervention: ogp160 MN/LAI-2 with alum
Number of subjects: 91
Study 26908741 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205) with ogp160 MN/LAI-2
Number of subjects: 91
Study 26908741 — intervention group
Group type: EXPERIMENTAL
Intervention: ogp160 protein alone
Number of subjects: 91
Study 26908741 — intervention group
Group type: EXPERIMENTAL
Intervention: prime-boost regimen (ALVAC-HIV and ogp160)
Number of subjects: 91
Study 26908741 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 25304863 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral cortisol
Number of subjects: 64
Study 25304863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23855759 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided TIVA with propofol and remifentanil
Number of subjects: 157
Study 23855759 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical practice TIVA with propofol and remifentanil
Number of subjects: 157
Study 20304608 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded HIPAA authorization form in the survey
Number of subjects: 1099
Study 20304608 — intervention group
Group type: COMPARATOR
Intervention: HIPAA form requiring signature for consent sent after the survey
Number of subjects: 1099
Study 20304608 — intervention group
Group type: COMPARATOR
Intervention: HIPAA form requiring signature and SSN for consent sent after the survey
Number of subjects: 1099
Study 18823299 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 14
Study 18823299 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 16364517 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum flexion with 20 kg load
Number of subjects: 0
Study 16364517 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum lateral bending with 20 kg load
Number of subjects: 0
Study 16364517 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum flexion and lateral bending with 20 kg load
Number of subjects: 0
Study 16364517 — intervention group
Group type: EXPERIMENTAL
Intervention: Various postures and loading conditions
Number of subjects: 0
Study 16364517 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretched muscle under loading conditions
Number of subjects: 0
Study 14529095 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming lesson group (5- to 6-week session)
Number of subjects: 8
Study 14529095 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 10944597 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ) at 200 mg/m(2)/day or 150 mg/m(2)/day for 5 days, repeated every 28 days
Number of subjects: 225
Study 10944597 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine (PCB) at 150 mg/m(2)/day or 125 mg/m(2)/day for 28 days, repeated every 56 days
Number of subjects: 225
Study 9005369 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 65
Study 9005369 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 65
Study 1728819 — intervention group
Group type: EXPERIMENTAL
Intervention: Test blends of edible oils with PMS ratio of approximately 0.8:1.3:1
Number of subjects: 26
Study 1728819 — intervention group
Group type: COMPARATOR
Intervention: Control dietary periods resembling Australian fat intake with PMS ratio of 0.4:0.9:1
Number of subjects: 26
Study 1728819 — intervention group
Group type: EXPERIMENTAL
Intervention: Test blends of edible oils with 16% trans fatty acid content
Number of subjects: 26
Study 30590861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention based on the Theory of Triadic Influence (TTI) including a 50 min motivational interview and online self-help material, with follow-up support via email and group therapy.
Number of subjects: 255
Study 30590861 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 122)
Number of subjects: 255
Study 28394521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose-rate brachytherapy using domestically manufactured I-125 seeds with a minimum therapeutic dose of 145 Gy, average of 57 seeds implanted (0.55 and 0.35 mCi per seed).
Number of subjects: 36
Study 28394521 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy combined with laparoscopic pelvic lymphadenectomy for intermediate risk group patients.
Number of subjects: 36
Study 26835147 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CYC) 0.5-1 g/m² monthly for first 6 months, then EC-MPS 720 mg/day until 12 months
Number of subjects: 59
Study 26835147 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg/day for first 6 months, then EC-MPS 720 mg/day until 12 months
Number of subjects: 59
Study 25132803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological preconditioning with sevoflurane
Number of subjects: 40
Study 25132803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 40
Study 22314029 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 260
Study 22314029 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 260
Study 20109120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra absorbency tampon (15 g to 18 g)
Number of subjects: 95
Study 20109120 — intervention group
Group type: COMPARATOR
Intervention: Super-plus absorbency tampon (12 g to 15 g)
Number of subjects: 95
Study 17555378 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg
Number of subjects: 20
Study 17555378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 75 mg
Number of subjects: 20
Study 17555378 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 20
Study 15642723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially adjusted randomization procedure
Number of subjects: 200
Study 15642723 — intervention group
Group type: COMPARATOR
Intervention: Efron's biased coin method
Number of subjects: 200
Study 11925281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 11925281 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 10215943 — intervention group
Group type: EXPERIMENTAL
Intervention: FVIII/vWF concentrate (IMMUNATE [STIM plus])
Number of subjects: 13
Study 10215943 — intervention group
Group type: EXPERIMENTAL
Intervention: FIX concentrate (IMMUNINE [STIM plus])
Number of subjects: 13
Study 10215943 — intervention group
Group type: COMPARATOR
Intervention: Control (reconstituted concentrate incubated under the same conditions)
Number of subjects: 13
Study 10215943 — intervention group
Group type: EXPERIMENTAL
Intervention: High purity FIX concentrate
Number of subjects: 13
Study 7529482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime)
Number of subjects: 40
Study 7529482 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin
Number of subjects: 40
Study 7529482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 40
Study 1706665 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGG plus Aspirin (group G)
Number of subjects: 0
Study 1706665 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (group A)
Number of subjects: 0
Study 399320 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg
Number of subjects: 0
Study 399320 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15 mg
Number of subjects: 0
Study 30277193 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review program
Number of subjects: 62
Study 30277193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 28749764 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-based drinking water filter
Number of subjects: 189
Study 25649680 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily risperidone
Number of subjects: 680
Study 25649680 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily olanzapine
Number of subjects: 680
Study 25649680 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily risperidone
Number of subjects: 680
Study 25649680 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily olanzapine
Number of subjects: 680
Study 23598785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic (VSL3® Ferring), 2 tablets a day for 5 days, followed by 1 tablet daily for 10 days
Number of subjects: 40
Study 23598785 — intervention group
Group type: COMPARATOR
Intervention: Vaginal clindamycin 100 mg daily for 15 days
Number of subjects: 40
Study 23598785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic (VSL3® Ferring)
Number of subjects: 40
Study 23598785 — intervention group
Group type: COMPARATOR
Intervention: Vaginal clindamycin
Number of subjects: 40
Study 21566302 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin alone
Number of subjects: 10
Study 21566302 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide alone
Number of subjects: 10
Study 21566302 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin plus furosemide
Number of subjects: 10
Study 18597165 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent expert evidence
Number of subjects: 0
Study 18597165 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent expert evidence
Number of subjects: 0
Study 18597165 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicial instruction
Number of subjects: 0
Study 16776048 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy during surgery
Number of subjects: 150
Study 16776048 — intervention group
Group type: COMPARATOR
Intervention: No music therapy during surgery (Control group)
Number of subjects: 150
Study 14687016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14687016 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg bid)
Number of subjects: 10
Study 14687016 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg bid)
Number of subjects: 10
Study 11374407 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression with antithymocyte (ATG) induction for 10 days, followed by maintenance therapy with cyclosporine (CsA) and mycophenolate mofetil (MMF).
Number of subjects: 100
Study 11374407 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression protocol
Number of subjects: 100
Study 9259427 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (E)
Number of subjects: 211
Study 9259427 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 211
Study 8299543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse acting as case manager working in conjunction with family doctors and community agencies to implement a treatment plan for depression.
Number of subjects: 0
Study 8299543 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medication (recommended introduction).
Number of subjects: 0
Study 3102407 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphosphonates (EHDP)
Number of subjects: 177
Study 3102407 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no drug therapy
Number of subjects: 177
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian clustering analysis
Number of subjects: 777
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic differentiation analysis
Number of subjects: 777
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalescent analyses
Number of subjects: 777
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological niche modelling (ENM)
Number of subjects: 777
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: FST analysis
Number of subjects: 777
Study 29897397 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographical scenario prediction
Number of subjects: 777
Study 28830083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 630
Study 28830083 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 630
Study 28830083 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 630
Study 23848141 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical activated protein C (APC)
Number of subjects: 12
Study 23848141 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 12
Study 23688331 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training for 45 minutes
Number of subjects: 0
Study 23688331 — intervention group
Group type: COMPARATOR
Intervention: No simulation training (Control)
Number of subjects: 0
Study 20848591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 302
Study 18279739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg/day for 4 weeks
Number of subjects: 20
Study 17157119 — intervention group
Group type: EXPERIMENTAL
Intervention: L100/HCTZ12.5
Number of subjects: 292
Study 17157119 — intervention group
Group type: COMPARATOR
Intervention: L100
Number of subjects: 292
Study 12925319 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antibiotic therapy (25 patients)
Number of subjects: 49
Study 12925319 — intervention group
Group type: COMPARATOR
Intervention: No preventive antibiotic therapy (24 patients)
Number of subjects: 49
Study 10678603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy with neck-stretching exercises
Number of subjects: 102
Study 10678603 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point injections with neck-stretching exercises
Number of subjects: 102
Study 10678603 — intervention group
Group type: COMPARATOR
Intervention: Neck-stretching exercises only (Control)
Number of subjects: 102
Study 9239167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-bar cryotherapy (Elase)
Number of subjects: 20
Study 9239167 — intervention group
Group type: COMPARATOR
Intervention: No ice-bar cryotherapy
Number of subjects: 20
Study 8461815 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted community care
Number of subjects: 181
Study 8461815 — intervention group
Group type: COMPARATOR
Intervention: Hospital clinic care (control)
Number of subjects: 181
Study 3491531 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training three times per week
Number of subjects: 56
Study 3491531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 56
Study 3491531 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 56
Study 3491531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 30877850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing feedback condition (comprehension quiz and answers provided after each text segment)
Number of subjects: 148
Study 30877850 — intervention group
Group type: COMPARATOR
Intervention: No-feedback condition (quiz and answers provided only at the end)
Number of subjects: 148
Study 28108429 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation treatment options with feedback and monitoring technology (FMT), video communication, and flexible exercise hours.
Number of subjects: 104
Study 28108429 — intervention group
Group type: COMPARATOR
Intervention: Home-based telerehabilitation scenarios with minimal physician supervision.
Number of subjects: 104
Study 28108429 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinic-based rehabilitation.
Number of subjects: 104
Study 26190629 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure and optimal screw pathways (at least 7 mm in diameter)
Number of subjects: 100
Study 26190629 — intervention group
Group type: EXPERIMENTAL
Intervention: EP (entry point) measurements
Number of subjects: 100